CD19 and B-cell chronic lymphocytic leukemia: Primary B-NHL cells (CD19 + CD20 + CD138-) from patients with MCL (n = 1), CLL (n = 2), and FL (n = 1), as well as a patient-derived xenograft DLBCL sample, were also assessed for BCMA expression.